Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
about
Identification of the citrate-binding site of human ATP-citrate lyase using X-ray crystallographyOf mice and men: novel insights regarding constitutive and recruitable brown adipocytesWeight management in obesity - past and presentGSK-3 as potential target for therapeutic intervention in cancerCellular bioenergetics as a target for obesity therapy.Brown fat as a therapy for obesity and diabetes.The utility of animal models to evaluate novel anti-obesity agents.Improved glucose tolerance in acyl CoA:diacylglycerol acyltransferase 1-null mice is dependent on diet.The influence of oral water load on energy expenditure and sympatho-vagal balance in obese and normal weight womenLiver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networksDetection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification.Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance.Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations.Brown adipose tissue: development, metabolism and beyond.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.Human brown adipose tissue as a target for obesity management; beyond cold-induced thermogenesis.Targeting adipose tissue.Effects of morroniside isolated from Corni Fructus on renal lipids and inflammation in type 2 diabetic mice.A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance.Genetics-based manipulation of adipose tissue sympathetic innervation.Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats.The Acute Effects of Nonstimulant Over-the-Counter Dietary Herbal Supplements on Resting Metabolic Rate.Herbal Bioenhancers in Veterinary Phytomedicine
P2860
Q24621078-0F924738-416E-4099-8F12-7D3DFBCD5025Q26751902-EA0272FE-46B0-45FC-9A71-1BE2B287E9E1Q26774747-268D49A5-66CE-4B46-B1F8-A06D8F6E8C41Q27013811-49BD00F9-66CE-4B67-B268-A8D03A5CBAC0Q33894407-E5F47A2B-5550-44FA-986B-5D8EE070D003Q34099153-363B6BB0-5D66-4AC7-B2D1-FDE792B48732Q35589958-A4B5046D-79B3-4801-BC93-1490A9C1F473Q35629184-5327A6B5-099C-4274-9397-510D35101514Q36524829-F0EB5FBC-5EB3-4D74-80CB-C3EFA201BF33Q36570690-2F82F996-5205-4386-A961-C97E399DDBCFQ36746883-2E9FEAEB-9EDF-4EF5-A11C-9569F7EE7D6EQ36932435-CD23EB9A-A7E5-4FA0-8A10-2F1179317339Q37316455-8E2DBEF8-B563-40F3-8343-63F3CC85BA02Q38117395-E4AE1225-6698-484D-9BB3-0C491F8945B2Q38758765-FD27B869-4031-442E-81C1-5C810CB32762Q38818675-052036E7-FB37-4D7F-9567-7510B9CCFCA6Q39434608-0D462B60-080F-41FB-ABE2-D884725BDB24Q41891082-81A33C75-76FC-46C6-A294-F4B60FA234DAQ43058445-EF74D7C5-3057-4AC6-87C9-852560BA9E73Q43195305-C584BF5F-EE07-428B-8FFF-0F1966A894F4Q45871412-811E801B-AF2E-47B3-8005-E41020718CD1Q48550172-35B3D28B-B247-44EF-BBEB-D6459990438CQ50990884-4BF4A79B-66CB-43EC-AA97-053C56A5BB8CQ58576453-B5D5FCC0-379F-46DC-B630-775C12A0B09B
P2860
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
@ast
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
@en
type
label
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
@ast
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
@en
prefLabel
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
@ast
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
@en
P2860
P1476
Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2006.00608.X
P577
2007-05-01T00:00:00Z